Servier Selects Genedata Screener to Contribute to its R&D Digital Transformation

Share Article

Leading enterprise software will integrate digital innovation efforts at Servier by automating data workflows and enabling R&D collaborators to benefit from scientific data integration and harmonization

News Image
After reviewing the options available to us, we concluded that Genedata Screener matches perfectly with our vision of being totally compatible with other digital innovation initiatives currently ongoing at Servier.

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that leading French biopharmaceutical company Laboratoires Servier has selected Genedata Screener® as part of its drug discovery research computational platform.

Servier chose Genedata Screener to establish a unified and universal data analysis system to extract insights from data from multiple sources, stored in various locations. The company will use Genedata Screener to significantly increase the speed and decrease the cost of medium- to high-throughput experiments employing complex technologies such as high-content screening and biophysical screening, including surface plasmon resonance, bio-layer interferometry, and thermal shift analysis, among others.

Genedata Screener federates data from in vitro screening assays, harmonizing and integrating all analysis workflows at Servier into one platform. To further boost Servier’s research efficiency, Genedata Screener will also integrate with instruments from manufacturers and data from contract research organizations that partner with the company. All elements of the platform are expected to be operational in 2020.

“Servier was looking at consolidating in vitro assay data analysis in a single state-of-the-art application explained Jean-Philippe Stephan, Ph.D., Director, Center of Excellence Pharmacological Screening, Compound Management and Biobanking at Laboratoires Servier. “After reviewing the options available to us, we concluded that Genedata Screener matches perfectly with our vision of being totally compatible with other digital innovation initiatives currently ongoing at Servier. Through the deployment of open and intuitive tools, our objective is truly to enable our collaborators to capitalize on all R&D data, interconnecting and federating multiple expert solutions to further optimize our innovation capabilities to better address patients’ unmet medical needs.”

Othmar Pfannes, Ph.D., CEO of Genedata, added, “We are honored to be selected by Servier as the ideal partner for its ambitious digital transformation project. Genedata Screener, a component of the Genedata Biopharma Platform—an interconnected suite of several Genedata systems that can be used stand-alone, or in combination to provide a fully integrated solution for biopharma R&D—is ideally suited to facilitate the company’s aims of establishing a world-leading R&D center with the ability to fully engage with data from any location in the world, to rapidly derive valuable scientific and business insights.”

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube

Miles Fisher-Pollard
Public Relations
Phone: +41 61 511 85 61

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Miles Fisher-Pollard
+41 61 511 85 61
Email >
Visit website